Pancreatitis treatment
Inventors
Velicelebi, Gonul • Stauderman, Kenneth • Dunn, Michael • Roos, Jack
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11311535-B2
Publication Date
2022-04-26
Expiration Date
Abstract
Compositions and methods related to the amelioration of pancreatitis through the pharmaceutical manipulation of calcium signaling are disclosed. Such compositions and methods may be used to ameliorate symptoms of acute or chronic pancreatitis or to reduce the chance or severity of pancreatitis in an individual at risk of the condition. In other embodiments, disclosed herein are compositions and methods related to the amelioration of viral diseases through the pharmaceutical manipulation of calcium signaling. In further embodiments, disclosed herein are compositions and methods related to the amelioration of Th17-induced diseases through the pharmaceutical manipulation of calcium signaling.
Core Innovation
The invention provides a method of ameliorating the symptoms of pancreatitis in a person by identifying a person in need of amelioration and administering an intracellular Calcium signaling inhibitor at a dose sufficient to ameliorate said symptoms. The intracellular Calcium signaling inhibitor is selected from a compound having the specified structure, or a pharmaceutically acceptable salt.
The invention targets intracellular Calcium signaling, which is described as relevant to Ca2+-driven premature trypsin activation and trypsinogen activation/auto-digestion. This mechanism is linked to pancreatic necrosis and imaging-confirmed necrosis, including necrosis determined by computed tomography (CT), and is framed as reducing processes associated with pancreatitis pathology.
The document further defines qualifying patient symptom and marker sets used to identify persons in need of amelioration. These include gastrointestinal signs and pancreatitis-related clinical measurements, inflammatory markers, and fecal and imaging findings such as steatorrhea, fecal fat excretion thresholds, fecal elastase thresholds, and CT-determined necrosis.
Claims Coverage
The claim set centers on one independent claim for ameliorating pancreatitis symptoms using an intracellular Calcium signaling inhibitor, with multiple dependent claims refining the qualifying patient presentation using symptom sets and diagnostic marker thresholds.
Intracellular Calcium signaling inhibitor for pancreatitis symptom amelioration
A method of ameliorating the symptoms of pancreatitis by identifying a person in need of amelioration and administering an intracellular Calcium signaling inhibitor selected from specified compound structures, or a pharmaceutically acceptable salt, at a dose sufficient to ameliorate said symptoms.
Qualifying pancreatitis symptom and clinical measurement set
The method is characterized in that the symptoms include at least one of a listed gastrointestinal and pancreatitis-related sign and clinical measurements.
CT-determined necrosis qualification
The method is characterized in that the symptoms include findings of necrosis determined by computed tomography (CT) scanning.
Fecal fat and fecal elastase threshold qualification
The method is defined by symptoms including steatorrhea and Sudan chemical staining of feces, fecal fat excretion of 7 grams or more over 24 hours on a 100 g fat diet, and fecal elastase in a stool sample at a value of less than 200 μg/g.
Multi-marker pancreatitis and inflammatory marker set
The method is further defined by symptoms that include at least one specified gastrointestinal, pancreatic, and inflammatory marker or abnormality.
Elevated serum amylase qualification
The method is further defined by symptoms that include elevated serum levels of amylase.
The claims cover administering an intracellular Calcium signaling inhibitor, selected from specified compound structures or salts, to ameliorate pancreatitis symptoms, with dependent claims narrowing eligibility through symptom and biomarker definitions including CT-determined necrosis, quantitative fecal fat and fecal elastase thresholds, and serum amylase.
Stated Advantages
Amelioration of pancreatitis symptoms.
Severity reduction, halting progression, and preventing occurrence.
Documented Applications
Ameliorating symptoms of acute pancreatitis and chronic pancreatitis in a person.
Prophylactic amelioration associated with pancreatitis using the intracellular Calcium signaling inhibitor framework.
Prophylactic indications for viral diseases including hemorrhagic fever virus.
Prophylactic indications for Th17-induced diseases involving T helper 17 cells (Th17) and IL-17 pathways.
Interested in licensing this patent?